Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 5, 2007, Pages

  Anderwald Stadler, Marietta ^a   Krebs, Michael ^a   Promintzer, Miriam ^a   Mandl, Martina ^a   Bischof, Martin G ^a   Nowotny, Peter ^a   Kästenbauer, Thomas ^a   Luger, Anton ^a   Prager, Rudolf ^a   Anderwald, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Appetite regulation; Free fatty acids; Ghrelin; Hyperinsulinemic clamp test

Indexed keywords

FATTY ACID; GHRELIN; GLUCOSE; INSULIN; OBESTATIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; FATTY ACID METABOLISM; FEMALE; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

BLOOD GLUCOSE; CHOLESTEROL; CREATININE; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GHRELIN; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 36148943883     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00330.2007     Document Type: Article

References (39)

1. Anderwald C, Anderwald-Stadler M, Promintzer M, Prager G, Mandl M, Nowotny P, Bischof MG, Wolzt M, Ludvik B, Kästenbauer T, Pacini G, Luger A, Krebs M. The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care 30: 2374-2380, 2007.
2. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, Nowotny P, Roden M, Waldhausl W. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51: 3025-3032, 2002.
3. Anderwald C, Brabant G, Bernroider E, Horn R, Brehm A, Waldhausl W, Roden M. Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 52: 1792-1798, 2003.
4. Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Peccoz P, Peracchi M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J Clin Endocrinol Metab 88: 701-704, 2003.
5. Bang AS, Soule SG, Yandle TG, Richards AM, Pemberton CJ. Characterisation of proghrelin peptides in mammalian tissue and plasma. J Endocrinol 192: 313-323, 2007.
6. Butler MG, Bittel DC. Plasma obestatin and ghrelin levels in subjects with Prader-Willi syndrome. Am J Med Genet A 143: 415-421, 2007.
7. Croset M, Rajas F, Zitoun C, Hurot JM, Montano S, Mithieux G. Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes 50: 740-746, 2001.
8. Damjanovic SS, Lalic NM, Pesko PM, Petakov MS, Jotic A, Miljic D, Lalic KS, Lukic L, Djurovic M, Djukic VB. Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients. J Clin Endocrinol Metab 91: 2574-2581, 2006.
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214-E223, 1979.
10. Dornonville de la Cour C, Lindstrom E, Norlen P, Hakanson R. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 120: 23-32, 2004.
11. Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: Should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 141: 1-7, 2007.
12. Gourcerol G, Tache Y. Obestatin - a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil 19: 161-165, 2007.
13. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 92: 1875-1880, 2007.
14. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik B. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 92: 1168-1171, 2007.
15. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47: 566-570, 2004.
16. Hosoda H, Kojima M, Kangawa K. Biological, physiological, and pharmacological aspects of ghrelin. J Pharm Sci 100: 398-410, 2006.
17. Katsuki A, Urakawa H, Gabazza EC, Murashima S, Nakatani K, Togashi K, Yano Y, Adachi Y, Sumida Y. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 151: 573-577, 2004.
18. Krebs M, Krssak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M, Nowotny P, Roth E, Waldhausl W, Roden M. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 51: 599-605, 2002.
19. Krebs M, Krssak M, Nowotny P, Weghuber D, Gruber S, Mlynarik V, Bischof M, Stingl H, Furnsinn C, Waldhausl W, Roden M. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 86: 2153-2160, 2001.
20. Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun 357: 264-269, 2007.
21. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med 38: 34-41, 2006.
22. Moechars D, Depoortere I, Moreaux B, de Smet B, Goris I, Hoskens L, Daneels G, Kass S, Ver Donck L, Peeters T, Coulie B. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptorknockout mouse. Gastroenterology 131: 1131-1141, 2006.
23. Murray CD, Kamm MA, Bloom SR, Emmanuel AV. Ghrelin for the gastroenterologist: history and potential. Gastroenterology 125: 1492-1502, 2003.
24. Natalucci G, Riedl S, Gleiss A, Zidek T, Frisch H. Spontaneous 24-h ghrelin secretion pattern in fasting subjects: maintenance of a meal-related pattern. Eur J Endocrinol 152: 845-850, 2005.
25. Nogueiras R, Pfluger P, Tovar S, Myrtha A, Mitchell S, Morris A, Perez-Tilve D, Vázquez MJ, Wiedmer P, Castañeda TR, Dimarchi R, Tschöp M, Schurmann A, Joost HG, Williams LM, Langhans W, Diéguez C. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 148: 21-26, 2006.
26. Packianathan IC, Fuller NJ, Peterson DB, Wright A, Coward WA, Finer N. Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the "Darwin study". Diabetologia 48: 222-229, 2005.
27. Pan W, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 27: 911-916, 2006.
28. Park WH, Oh YJ, Kim GY, Kim SE, Paik KH, Han SJ, Kim AH, Chu SH, Kwon EK, Kim SW, Jin DK. Obestatin is not elevated or correlated with insulin in children with Prader-Willi syndrome. J Clin Endocrinol Metab 92: 229-234, 2006.
29. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52: 2546-2553, 2003.
30. Qi X, Li L, Yang G, Liu J, Li K, Tang Y, Liou H, Boden G. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66: 593-597, 2007.
31. Schutte AE, Huisman HW, Schutte R, van Rooyen JM, Malan L, Malan NT. Aging influences the level and functions of fasting plasma ghrelin levels: The POWIRS-Study. Regul Pept 139: 65-71, 2007.
32. Seoane LM, Al Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 29: RC13-RC15, 2006.
33. Tolle V, Bassant MH, Zizzari P, Poindessous-Jazat F, Tomasetto C, Epelbaum J, Bluet-Pajot MT. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology 143: 1353-1361, 2002.
34. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86: 5992, 2001.
35. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540-2547, 2001.
36. Yamamoto D, Ikeshita N, Daito R, Herningtyas EH, Toda K, Takahashi K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats. Regul Pept 138: 141-144, 2007.
37. Zhang JV, Klein C, Ren PG, Kass S, Ver Donck L, Moechars D, Hsueh AJ. Response to Comment on "Obestatin, a Peptide Encoded by the Ghrelin Gene Opposes Ghrelin's Effects on Food Intake" (Online). Science 315. http://www.sciencemag.org/cgi/content/full/315/5813/766d[1 Nov. 2007].
38. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310: 996-999, 2005.
39. Zizzari P, Longchamps R, Epelbaum J, Bluet-Pajot MT. Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 148: 1648-1653, 2007.